Targeted tumor desialylation by engineered probiotic reprograms the tumor microenvironment to potentiate immunotherapy
Tumor hypersialylation drives immunosuppression and limits immunotherapy efficacy by shielding tumor cells and engaging inhibitory immune receptors. Here,